Dr. Martens Plc (GB:DOCS)
LSE:DOCS
DOCS Stock Chart & Stats
64.20 p
-1.05 p(-1.49%)
At close: 4:00 PM EST
64.20 p
-1.05 p(-1.49%)
Day’s Range― - ―
52-Week Range43.02 p - 100.87 p
Previous CloseN/A
Volume189.83K
Average Volume (3M)1.82M
Market Cap
£620.65M
Enterprise Value921.96M
Total Cash (Recent Filing)£95.70M
Total Debt (Recent Filing)£397.10M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 28, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding967,472,960
10 Day Avg. Volume1,078,739
30 Day Avg. Volume1,820,978
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£93.75Price Target Upside46.03% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)£815.42M
Bulls Say, Bears Say
Bulls Say
Free Cash FlowA significant increase in free cash flow strengthens internal funding for stores, inventory and marketing without relying on external capital. Reliable cash conversion supports reinvestment, debt paydown and resilience, improving the company's ability to execute strategy over the next 2–6 months.
Debt ReductionLower net bank debt and a net debt-to-EBITDA around 2.1x materially improve financial flexibility. Reduced leverage cuts interest exposure and frees cash for DTC expansion or product investment, giving management room to pursue growth while limiting solvency risk in the medium term.
Margin & Pricing PowerHigh gross margins and rising full-price DTC sales indicate durable pricing power and better revenue quality. Sustained full-price sell-through supports healthier unit economics, reduces reliance on promotions, and helps rebuild operating margins over several quarters.
Bears Say
Declining RevenueA persistent top-line decline undermines operating leverage and cash generation potential if not reversed. Falling revenue constrains margin recovery and forces tougher trade-offs on marketing, inventory and pricing, making sustained profit improvement harder over the next few quarters.
Return On Equity DropA collapse in ROE signals a sharp deterioration in the company's ability to generate returns on shareholder capital. This sustained weakness can erode investor confidence, limit access to equity financing, and reflect deeper issues in profitability or capital allocation.
Regional/Product HeadwindsDeclines in EMEA DTC, ongoing boots/sandals product challenges and tariff costs (noted separately) are structural headwinds that hurt core categories and complicate inventory, pricing and margin management. These issues can persist across seasons and regions if product-market fit isn't fixed.
Dr. Martens Plc News
DOCS FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest share price was 43.02 p and its highest was 100.87 p in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is £620.65M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 52 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -0.009 p earnings per share for the quarter, the consensus estimate of -0.009 p by 0 p.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc pays a Semiannually dividend of 0.85 p which represents an annual dividend yield of 3.36%. See more information on Dr. Martens Plc dividends here
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.05.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,472,960 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -0.009 p in its last earnings report, expectations of -0.009 p. Following the earnings report the stock price went down -9.558%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in GB:DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£93.75 (46.03% Upside)
£93.75 (46.03% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.81%
12-Months-Change
Fundamentals
Return on Equity
4.40%
Trailing 12-Months
Asset Growth
-7.19%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
DOCS Stock 12 Month Forecast
Average Price Target
93.75 p
▲(46.03% Upside)
Technical Analysis
Options Prices
Currently, No data available
---